Tag: Merck
-
Merck’s Remigromig Meets Phase 2b/3 Endpoint in Diabetic Macular Edema
Both remigromig doses were noninferior to ranibizumab at Week 52 in the Phase 2b/3 BRUNELLO trial, but safety imbalances and commercial differentiation require further data.
-
How Moderna’s Personalized mRNA Cancer Therapy Trains the Immune System
This BP Science explainer shows how intismeran uses patient-specific tumor mutations to create a personalized mRNA neoantigen therapy, activate tumor-specific T cells, and work together with Keytruda to sustain anti-tumor immunity.
-
Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
Moderna and Merck’s personalized mRNA cancer therapy intismeran met both recurrence-free survival and distant metastasis-free survival endpoints in Phase 3 melanoma, marking a major milestone for individualized mRNA-based cancer treatment.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.